← All trials
NCT06478602
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2023
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2026
- First posted
- Jun 27, 2024
- Last posted
- Jul 31, 2024
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Academic Emergency County Hospital SibiuLead sponsor
- Academic Emergency County Hospital SibiuSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.